Company Encyclopedia
View More
name
Azenta
AZTA.US
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services.
768.07 B
AZTA.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking31/62
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.40%C
    • Profit Margin-9.39%D
    • Gross Margin45.52%B
  • Growth ScoreC
    • Revenue YoY3.55%C
    • Net Profit YoY66.18%A
    • Total Assets YoY-1.94%D
    • Net Assets YoY-2.31%D
  • Cash ScoreD
    • Cash Flow Margin-1064.90%E
    • OCF YoY3.55%C
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreA
    • Gearing Ratio16.15%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Is Azenta’s Buyback and M&A Push Recalibrating the Investment Case For Azenta (AZTA)?

    Azenta, Inc. announced a US$250 million share repurchase program through 2028 and plans for disciplined M&A focused on high-margin, recurring-revenue life sciences assets. Management highlighted 60 potential acquisition targets with strict financial filters. The buyback and M&A push aim to reshape Azenta's medium-term investment narrative, despite risks from softer demand. Azenta projects $684.6 million revenue and $34.5 million earnings by 2028, with a fair value estimate of $39.83, a 16% upside to its current price.

    Simplywall·
    US
    AZTA
    +0.03%
    Simplywall·
    US
    AZTA
    +0.03%

    Azenta, Inc. $AZTA Shares Sold by Squarepoint Ops LLC

    Squarepoint Ops LLC reduced its stake in Azenta, Inc. by 54.3% in Q2, now owning 56,866 shares worth $1,750,000. Several other institutional investors also adjusted their positions in AZTA. Azenta's stock opened at $34.50 with a market cap of $1.59 billion. The company reported Q2 earnings of $0.21 per share and initiated a $250 million share repurchase program. Analysts have mixed ratings on the stock, with an average target price of $38.60.

    Market Beat·
    US
    AZTA
    +0.03%
    Market Beat·
    US
    AZTA
    +0.03%

    Azenta Inc. Announces Date for Upcoming Annual Shareholders Meeting

    Azenta Inc. will hold its annual shareholders meeting virtually on January 28, 2026. Shareholders will vote on the election of ten directors and approve the compensation of the company's named executive officers. The original content was published via EDGAR by Azenta Inc. on December 18, 2025.

    Reuters·
    US
    AZTA
    +0.03%
    Reuters·
    US
    AZTA
    +0.03%

    Stock Repurchase Program Declared by Azenta (NASDAQ:AZTA)

    Azenta (NASDAQ:AZTA) announced a $250 million stock buyback plan, allowing the repurchase of up to 14.9% of its shares, indicating the board's belief that shares are undervalued. Analysts have mixed ratings on Azenta, with some upgrading to 'buy' and others downgrading to 'sell'. The stock recently rose 2.7% to $37.50, with a market cap of $1.72 billion. Azenta reported quarterly earnings of $0.21 per share, slightly above estimates, with revenue up 5.7% year-over-year.

    Market Beat·
    US
    AZTA
    +0.03%
    Market Beat·
    US
    AZTA
    +0.03%

    Health Care Up on Earnings Optimism - Health Care Roundup

    Health-care companies rose amid optimism about earnings growth in the sector. Shares of Danish obesity drug maker Novo Nordisk rose by 5.8%, recouping some recent losses. Rival Eli Lilly rose modestly, but remains close to all-time highs. Shares of life-sciences firm Azenta rose after the company's board of directors approved the repurchase of up to $250 million of common stock. Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires 12-10-25 1708ET

    marketscreener·
    US
    AZTA
    +0.03%
    US
    NVO
    +7.30%
    US
    LLY
    -0.45%
    marketscreener·
    US
    AZTA
    +0.03%
    US
    NVO
    +7.30%
    US
    LLY
    -0.45%
    © 2025 Longbridge｜Disclaimer